Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (24) 24
female (15) 15
male (15) 15
adult (14) 14
index medicus (14) 14
middle aged (13) 13
adolescent (9) 9
aged (9) 9
infectious diseases (9) 9
medicine, general & internal (9) 9
treatment outcome (9) 9
double-blind method (8) 8
clinical trials (7) 7
drug therapy (6) 6
hiv infections - drug therapy (6) 6
immunology (6) 6
raltegravir potassium (6) 6
safety (6) 6
viral load (6) 6
abridged index medicus (5) 5
drug therapy, combination (5) 5
integrase inhibitor raltegravir (5) 5
internal medicine (5) 5
microbiology (5) 5
rna, viral - blood (5) 5
young adult (5) 5
actin (4) 4
antiretroviral drugs (4) 4
care and treatment (4) 4
cd4 lymphocyte count (4) 4
child (4) 4
efficacy (4) 4
evaluation (4) 4
genotype (4) 4
health aspects (4) 4
human immunodeficiency virus--hiv (4) 4
infant (4) 4
pyrrolidinones - therapeutic use (4) 4
raltegravir (4) 4
2008 recommendations (3) 3
aged, 80 and over (3) 3
amphotericin b (3) 3
animals (3) 3
anti-bacterial agents - therapeutic use (3) 3
anti-hiv agents - therapeutic use (3) 3
antibiotics (3) 3
antiretroviral drug-resistance (3) 3
candidiasis (3) 3
candidiasis - drug therapy (3) 3
children (3) 3
combination therapy (3) 3
drug dosages (3) 3
drugs (3) 3
gastroenteritis - virology (3) 3
hiv infections - virology (3) 3
hiv integrase inhibitors - therapeutic use (3) 3
hiv-1 - genetics (3) 3
infection (3) 3
mice (3) 3
mortality (3) 3
protease inhibitors (3) 3
rotavirus - classification (3) 3
rotavirus vaccines - immunology (3) 3
society-usa panel (3) 3
therapy (3) 3
united-states (3) 3
amphotericin b - administration & dosage (2) 2
amphotericin b - adverse effects (2) 2
amphotericin b - therapeutic use (2) 2
amphotericin-b (2) 2
anti-hiv agents - adverse effects (2) 2
antifungal agents - administration & dosage (2) 2
antifungal agents - adverse effects (2) 2
antifungal agents - therapeutic use (2) 2
benzoxazines - therapeutic use (2) 2
calcium (2) 2
caspofungin (2) 2
ceftriaxone (2) 2
child, preschool (2) 2
clinical trials, phase iii as topic (2) 2
daily lopinavir/ritonavir (2) 2
diarrhea (2) 2
dosage and administration (2) 2
double-blind (2) 2
drug administration schedule (2) 2
drug resistance (2) 2
efavirenz (2) 2
emtricitabine (2) 2
endocarditis, bacterial - etiology (2) 2
endothelium (2) 2
epidemiology (2) 2
ertapenem (2) 2
gastroenteritis (2) 2
gastroenterology & hepatology (2) 2
gelsolin (2) 2
gelsolin - blood (2) 2
genotype & phenotype (2) 2
gram-negative bacilli (2) 2
growth-factor (2) 2
hepacivirus - genetics (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
by Eron, Joseph J, Prof and Rockstroh, Jürgen K, MD and Reynes, Jacques, Prof and Andrade-Villanueva, Jaime, MD and Ramalho-Madruga, Jose Valdez, MD and Bekker, Linda-Gail, MD and Young, Benjamin, MD and Katlama, Christine, MD and Gatell-Artigas, Jose Maria, MD and Arribas, Jose R, MD and Nelson, Mark, MD and Campbell, Havilland, BS and Zhao, Jing, PhD and Rodgers, Anthony J, MS and Rizk, Matthew L, PhD and Wenning, Larissa, PhD and Miller, Michael D, PhD and Hazuda, Daria, PhD and DiNubile, Mark J, MD and Leavitt, Randi, MD and Isaacs, Robin, MD and Robertson, Michael N, MD and Sklar, Peter, MD and Nguyen, Bach-Yen, Dr and QDMRK Investigators
Lancet Infectious Diseases, The, ISSN 1473-3099, 2011, Volume 11, Issue 12, pp. 907 - 915
Summary Background Twice-daily raltegravir with once-daily tenofovir-emtricitabine is an effective initial antiretroviral regimen for patients with HIV-1. On... 
Infectious Disease | INTEGRASE INHIBITOR RALTEGRAVIR | INFECTIOUS DISEASES | DAILY ATAZANAVIR/RITONAVIR | SAFETY | NAIVE HIV-1-INFECTED PATIENTS | COMBINATION THERAPY | DOUBLE-BLIND | INFECTION | PATIENTS 96-WEEK EFFICACY | STRAND TRANSFER | DAILY LOPINAVIR/RITONAVIR | Drug Administration Schedule | HIV-1 - drug effects | HIV Infections - virology | Humans | Middle Aged | Kaplan-Meier Estimate | Pyrrolidinones - pharmacokinetics | Pyrrolidinones - therapeutic use | Male | Treatment Outcome | CD4 Lymphocyte Count | HIV Integrase Inhibitors - pharmacokinetics | HIV Integrase Inhibitors - administration & dosage | Viral Load | Pyrrolidinones - administration & dosage | Young Adult | HIV Integrase Inhibitors - therapeutic use | Adult | Female | HIV Infections - drug therapy | HIV Infections - mortality | Aged | Raltegravir Potassium | Antiviral agents | Product development | Dosage and administration | HIV (Viruses) | Consulting services
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials
by Eron, Joseph J, Prof and Young, Benjamin, MD and Cooper, David A, Prof and Youle, Michael, MD and DeJesus, Edwin, MD and Andrade-Villanueva, Jaime, MD and Workman, Cassy, MD and Zajdenverg, Roberto, MD and Fätkenheuer, Gerd, Prof and Berger, Daniel S, MD and Kumar, Princy N, MD and Rodgers, Anthony J, MS and Shaughnessy, Melissa A, MS and Walker, Monica L, BS and Barnard, Richard JO, PhD and Miller, Michael D, PhD and DiNubile, Mark J, MD and Nguyen, Bach-Yen, MD and Leavitt, Randi, MD and Xu, Xia, PhD and Sklar, Peter, Dr and SWITCHMRK 1 Investigator and SWITCHMRK 2 Investigator and SWITCHMRK 1 and 2 investigators
Lancet, The, ISSN 0140-6736, 2010, Volume 375, Issue 9712, pp. 396 - 407
Summary Background To reduce lipid abnormalities and other side-effects associated with antiretroviral regimens containing lopinavir-ritonavir, patients might... 
Internal Medicine | INTEGRASE INHIBITOR RALTEGRAVIR | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | EFFICACY | SAFETY | COMBINATION THERAPY | SOCIETY-USA PANEL | ANTIRETROVIRAL THERAPY | 2008 RECOMMENDATIONS | TREATMENT-NAIVE PATIENTS | DAILY LOPINAVIR/RITONAVIR | Humans | Middle Aged | Male | RNA, Viral - blood | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Cholesterol, LDL - blood | Female | Drug Therapy, Combination | Raltegravir Potassium | HIV Infections - blood | Pyrrolidinones - adverse effects | Viremia - physiopathology | Double-Blind Method | Drug Administration Schedule | HIV-1 - drug effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Lopinavir | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Pyrrolidinones - therapeutic use | Cholesterol, LDL - drug effects | Treatment Outcome | HIV-1 - genetics | Viremia - virology | HIV Infections - drug therapy | RNA, Viral - drug effects | Studies | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
by Lennox, Jeffrey L, Prof and DeJesus, Edwin, MD and Lazzarin, Adriano, Prof and Pollard, Richard B, Prof and Madruga, Jose Valdez Ramalho, MD and Berger, Daniel S, MD and Zhao, Jing, PhD and Xu, Xia, PhD and Williams-Diaz, Angela, BS and Rodgers, Anthony J, MS and Barnard, Richard JO, PhD and Miller, Michael D, PhD and DiNubile, Mark J, MD and Nguyen, Bach-Yen, MD and Leavitt, Randi, MD and Sklar, Peter, Dr and STARTMRK Investigators and STARTMRK investigators
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9692, pp. 796 - 806
Summary Background Use of raltegravir with optimum background therapy is effective and well tolerated in treatment-experienced patients with... 
Internal Medicine | INTEGRASE INHIBITOR RALTEGRAVIR | NEUROPSYCHIATRIC ADVERSE EVENTS | MEDICINE, GENERAL & INTERNAL | TRANSMISSION | REPLICATION | ANTIRETROVIRAL DRUG-RESISTANCE | PHASE-II | SOCIETY-USA PANEL | PREVALENCE | 2008 RECOMMENDATIONS | NEVIRAPINE | Prognosis | Humans | Male | Viral Load | Tenofovir | HIV Infections - immunology | Deoxycytidine - therapeutic use | Adenine - therapeutic use | Pyrrolidinones - pharmacology | Adult | Anti-HIV Agents - therapeutic use | Female | Safety | Drug Therapy, Combination | Raltegravir Potassium | Emtricitabine | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | HIV Infections - virology | Pyrrolidinones - therapeutic use | Treatment Outcome | HIV-1 - genetics | Benzoxazines - therapeutic use | Analysis of Variance | HIV Infections - drug therapy | RNA, Viral - drug effects | Deoxycytidine - analogs & derivatives | Dosage and administration | Drug therapy, Combination | Comparative analysis | Drug therapy | Health aspects | Efavirenz | HIV infection | Raltegravir | Antiretroviral drugs | Protease inhibitors | Drug resistance | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Transesophageal Echocardiograms in Patients with Catheter-derived Staphylococcus aureus Bacteremia
by DiNubile, Mark J., MD
American Journal of Medicine, The, ISSN 0002-9343, 2012, Volume 125, Issue 7, pp. 628 - 629
Internal Medicine | CRITERIA | DIAGNOSIS | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | THERAPY | INFECTION | ENDOCARDITIS | CHILDREN | Endocarditis, Bacterial - diagnostic imaging | Endocarditis, Bacterial - drug therapy | Staphylococcal Infections - drug therapy | Anti-Infective Agents - administration & dosage | Endocarditis, Bacterial - etiology | Humans | Catheters, Indwelling - adverse effects | Echocardiography, Transesophageal - utilization | Iatrogenic Disease | Staphylococcal Infections - diagnostic imaging | Staphylococcus aureus | Staphylococcal Infections - etiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Invasive candidiasis treated in the intensive care unit: Observations from a randomized clinical trial
by DiNubile, Mark J., MD and Lupinacci, Robert J., MS and Strohmaier, Kim M., BS and Sable, Carole A., MD and Kartsonis, Nicholas A., MD
Journal of Critical Care, ISSN 0883-9441, 2007, Volume 22, Issue 3, pp. 237 - 244
Abstract Objectives The objectives of this study were to contrast risk factors, microbiology, and outcomes in patients with invasive candidiasis treated in an... 
Critical Care | Invasive candidiasis | Candidemia | Amphotericin B | Intensive care unit | Caspofungin | NON-NEUTROPENIC PATIENTS | SURGICAL-PATIENTS | RISK-FACTORS | invasive candidiasis | amphotericin B | AMPHOTERICIN-B | candidemia | caspofungin | PROSPECTIVE MULTICENTER | NOSOCOMIAL CANDIDEMIA | intensive care unit | CRITICALLY-ILL PATIENTS | BLOOD-STREAM INFECTIONS | EPIDEMIOLOGY | CRITICAL CARE MEDICINE | Recurrence | United States - epidemiology | Antifungal Agents - adverse effects | Intensive Care Units | Humans | Middle Aged | Risk Factors | Candidiasis - mortality | Logistic Models | Male | Treatment Outcome | Amphotericin B - adverse effects | Echinocandins - administration & dosage | Echinocandins - adverse effects | Candidiasis - drug therapy | Fungemia - drug therapy | Drug-Related Side Effects and Adverse Reactions | Survival Analysis | Amphotericin B - administration & dosage | Female | Retrospective Studies | Antifungal Agents - administration & dosage | Lipopeptides | Clinical trials | Candidiasis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection
by Steigbigel, Roy T and Cooper, David A and Kumar, Princy N and Eron, Joseph E and Schechter, Mauro and Markowitz, Martin and Loutfy, Mona R and Lennox, Jeffrey L and Gatell, Jose M and Rockstroh, Jurgen K and Katlama, Christine and Yeni, Patrick and Lazzarin, Adriano and Clotet, Bonaventura and Zhao, Jing and Chen, Joshua and Ryan, Desmond M and Rhodes, Rand R and Killar, John A and Gilde, Lucinda R and Strohmaier, Kim M and Meibohm, Anne R and Miller, Michael D and Hazuda, Daria J and Nessly, Michael L and DiNubile, Mark J and Isaacs, Robin D and Nguyen, Bach-Yen and Teppler, Hedy and BENCHMRK Study Teams
The New England Journal of Medicine, ISSN 0028-4793, 07/2008, Volume 359, Issue 4, pp. 339 - 354
For patients infected with multidrug-resistant human immunodeficiency virus type 1 (HIV-1), therapeutic options are limited. Raltegravir is a new molecule that... 
INTEGRASE INHIBITOR RALTEGRAVIR | MEDICINE, GENERAL & INTERNAL | RECONSTITUTION INFLAMMATORY SYNDROME | IMMUNE RECONSTITUTION | TREATMENT-EXPERIENCED PATIENTS | ANTIRETROVIRAL DRUG-RESISTANCE | SALVAGE THERAPY | HIV-1-INFECTED PATIENTS | RANDOMIZED CONTROLLED-TRIAL | PLACEBO-CONTROLLED TRIAL | PROTEASE INHIBITORS | Neoplasms - etiology | Follow-Up Studies | Humans | Middle Aged | Drug Resistance, Viral | Male | RNA, Viral - blood | Viral Load | HIV-1 - isolation & purification | Adult | Female | Drug Therapy, Combination | Raltegravir Potassium | Double-Blind Method | Organic Chemicals - adverse effects | Organic Chemicals - therapeutic use | Logistic Models | Treatment Outcome | CD4 Lymphocyte Count | HIV-1 - genetics | Pyrrolidinones | HIV Integrase Inhibitors - adverse effects | Adolescent | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Aged | Placebos | Evaluation | HIV patients | Care and treatment | Raltegravir | Clinical trials | Antiretroviral drugs | Drug therapy | Drug dosages | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
by Cooper, David A and Steigbigel, Roy T and Gatell, Jose M and Rockstroh, Jurgen K and Katlama, Christine and Yeni, Patrick and Lazzarin, Adriano and Clotet, Bonaventura and Kumar, Princy N and Eron, Joseph E and Schechter, Mauro and Markowitz, Martin and Loutfy, Mona R and Lennox, Jeffrey L and Zhao, Jing and Chen, Joshua and Ryan, Desmond M and Rhodes, Rand R and Killar, John A and Gilde, Lucinda R and Strohmaier, Kim M and Meibohm, Anne R and Miller, Michael D and Hazuda, Daria J and Nessly, Michael L and DiNubile, Mark J and Isaacs, Robin D and Teppler, Hedy and Nguyen, Bach-Yen and BENCHMRK Study Teams
The New England Journal of Medicine, ISSN 0028-4793, 07/2008, Volume 359, Issue 4, pp. 355 - 365
In subgroups of two phase 3 studies, patients with high-risk features for failure of antiretroviral therapy, such as a low CD4 count, high base-line level of... 
INTEGRASE INHIBITOR RALTEGRAVIR | TRIALS | MEDICINE, GENERAL & INTERNAL | THERAPY | EFFICACY | SAFETY | TREATMENT-EXPERIENCED PATIENTS | PREVALENCE | STRAND TRANSFER | ENFUVIRTIDE | HIV-1 | Humans | Middle Aged | Male | RNA, Viral - blood | Viral Load | Adult | Female | Drug Therapy, Combination | Raltegravir Potassium | Double-Blind Method | Organic Chemicals - adverse effects | Organic Chemicals - therapeutic use | Genotype | Treatment Outcome | CD4 Lymphocyte Count | Drug Resistance, Viral - genetics | Phenotype | Pyrrolidinones | HIV Integrase - genetics | HIV Integrase Inhibitors - adverse effects | Adolescent | HIV Integrase Inhibitors - therapeutic use | HIV Infections - drug therapy | Aged | Mutation | Drug resistance in microorganisms | Evaluation | Care and treatment | Analysis | Placebos | HIV patients | Raltegravir | Clinical trials | Antiretroviral drugs | Genotype & phenotype | Drug resistance | Human immunodeficiency virus--HIV | Clinical outcomes | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses
by Lennox, Jeffrey L and DeJesus, Edwin and Berger, Daniel S and Lazzarin, Adriano and Pollard, Richard B and Madruga, Jose Valdez Ramalho and Zhao, Jing and Wan, Hong and Gilbert, Christopher L and Teppler, Hedy and Rodgers, Anthony J and Barnard, Richard J. O and Miller, Michael D and DiNubile, Mark J and Nguyen, Bach-Yen and Leavitt, Randi and Sklar, Peter and STARTMRK Investigators
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 09/2010, Volume 55, Issue 1, pp. 39 - 48
Background: We analyzed the 96-week results in the overall population and in prespecified subgroups from the ongoing STARTMRK study of treatment-naive... 
Integrase inhibitor | Efavirenz | STARTMRK | Raltegravir | MK-0518 | Treatment-naive patients | INFECTIOUS DISEASES | MULTICENTER | COMBINATION THERAPY | integrase inhibitor | raltegravir | IMMUNOLOGY | ANTIRETROVIRAL DRUG-RESISTANCE | SOCIETY-USA PANEL | HIV-1 INFECTION | 2008 RECOMMENDATIONS | treatment-naive patients | efavirenz | Pyrrolidinones - adverse effects | Anti-HIV Agents - adverse effects | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Pyrrolidinones - therapeutic use | Benzoxazines - adverse effects | Male | RNA, Viral - blood | Treatment Outcome | CD4 Lymphocyte Count | Viral Load | Benzoxazines - therapeutic use | Young Adult | HIV-1 - isolation & purification | Adult | Anti-HIV Agents - therapeutic use | Female | HIV Infections - drug therapy | Aged | Antiretroviral Therapy, Highly Active - methods | Raltegravir Potassium
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Serotype replacement after pneumococcal vaccination/Authors' reply
by Kim Mulholland and Catherine Satzke and William P Hausdorff and Melissa K Van Dyke and Thierry Van Effelterre and Mark J DiNubile and Daniel M Weinberger and Richard Malley and Marc Lipsitch
The Lancet, ISSN 0140-6736, 04/2012, Volume 379, Issue 9824, p. 1387
  [...] the studies that Hausdorff and colleagues emphasise as showing low levels of reported replacement should be interpreted with care given the length of... 
Immunization | Pneumonia | Meningitis | Vaccines | Streptococcus infections
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text A Randomized Double-Blind Study of Caspofungin versus Amphotericin for the Treatment of Candidal Esophagitis
by Alvaro Villanueva and Eduardo G. Arathoon and Eduardo Gotuzzo and Rayanne S. Berman and Mark J. DiNubile and Carole A. Sable
Clinical Infectious Diseases, ISSN 1058-4838, 11/2001, Volume 33, Issue 9, pp. 1529 - 1535
Caspofungin is a new broad-spectrum antifungal drug. A multicenter, double-blind, randomized trial was conducted to assess the efficacy, safety, and... 
Antifungals | Candida albicans | Candidiasis | Azoles | Major Articles | Antimicrobials | Esophagitis | Viruses | Experimentation | Infections | Dosage | ECHINOCANDIN ANTIFUNGAL | INFECTIOUS DISEASES | VIRUS-INFECTED PATIENTS | OROPHARYNGEAL CANDIDIASIS | SUSCEPTIBILITY | MICROBIOLOGY | IMMUNOLOGY | ORAL CANDIDIASIS | DUBLINIENSIS | ANTIFUNGAL AGENTS | FLUCONAZOLE-RESISTANT CANDIDA | ALBICANS | IN-VITRO ACTIVITY | Double-Blind Method | Peptides | Consumer Product Safety | Humans | Middle Aged | Drug Tolerance | Male | Candidiasis - microbiology | Esophagitis - pathology | Antifungal Agents - therapeutic use | Esophagitis - microbiology | Peptides, Cyclic | Anti-Bacterial Agents - therapeutic use | Candidiasis - drug therapy | Echinocandins | Esophagitis - drug therapy | Adult | Female | Aged | Esophagoscopy - methods | Amphotericin B - therapeutic use | Candidiasis - pathology | Lipopeptides | Evaluation | Amphotericin B | Drug therapy | Thrush (Mouth disease)
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin
by Jacobson, Ira M and Marcellin, Patrick and Zeuzem, Stefan and Sulkowski, Mark S and Esteban, Rafael and Poordad, Fred and Bruno, Savino and Burroughs, Margaret H and Pedicone, Lisa D and Boparai, Navdeep and Deng, Weiping and DiNubile, Mark J and Gottesdiener, Keith M and Brass, Clifford A and Albrecht, Janice K and Bronowicki, Jean‐Pierre
Hepatology, ISSN 0270-9139, 08/2012, Volume 56, Issue 2, pp. 567 - 575
In comparison with peginterferon/ribavirin alone, boceprevir with peginterferon/ribavirin significantly improves sustained virological response (SVR) rates in... 
VIRUS-INFECTION | TELAPREVIR | THERAPY | RNA | PEGINTERFERON-ALPHA-2A | RANDOMIZED-TRIAL | GASTROENTEROLOGY & HEPATOLOGY | ALPHA-2B PLUS RIBAVIRIN | VIROLOGICAL RESPONSE | Humans | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | RNA, Viral - blood | Drug Monitoring - methods | Recombinant Proteins - adverse effects | Clinical Trials, Phase III as Topic | Ribavirin - administration & dosage | Treatment Failure | Retrospective Studies | Drug Therapy, Combination | Databases, Factual | Hepacivirus - drug effects | Proline - administration & dosage | Proline - analogs & derivatives | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Randomized Controlled Trials as Topic | Interferon-alpha - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Proline - adverse effects | Interferon-alpha - adverse effects | Hepatitis | Genotype & phenotype | Interferon | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights